Related Experiment Video

Updated: Apr 28, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
08:32

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes

Published on: May 23, 2025

1.4K

A rationale to target the SWI/SNF complex for cancer therapy

Anja F Hohmann1, Christopher R Vakoc1

  • 1Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA.

Trends in Genetics : TIG
|June 17, 2014
PubMed

Insights

The SWI/SNF chromatin-remodeling complex is crucial for preventing cancer. SWI/SNF-mutant cancers and certain leukemias show vulnerabilities that can be targeted for new cancer therapies.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Biology

Background:

  • The SWI/SNF complex is vital for gene regulation, cell development, and preventing tumor formation.
  • Mutations inactivating SWI/SNF subunits are present in approximately 20% of human cancers.
  • SWI/SNF function is essential for maintaining normal cellular processes and preventing oncogenesis.

Purpose of the Study:

  • To review emerging evidence on the role of SWI/SNF in cancer.
  • To highlight SWI/SNF as a potential tumor-dependency and drug target.
  • To explore therapeutic strategies targeting SWI/SNF vulnerabilities.

Main Methods:

  • Review of recent scientific literature and studies.
  • Analysis of genetic mutations and their impact on SWI/SNF function.
  • Investigation of cancer dependencies and therapeutic vulnerabilities.

Main Results:

  • SWI/SNF-mutant cancers exhibit synthetic lethal interactions with residual SWI/SNF complexes.
  • Certain acute leukemias and small cell lung cancers are sensitive to inhibition of the SWI/SNF ATPase subunit BRG1.
  • SWI/SNF is implicated as a critical factor in tumor growth and survival across various cancers.

Conclusions:

  • SWI/SNF is a significant factor in cancer development and progression.
  • Targeting SWI/SNF vulnerabilities presents a promising therapeutic avenue for cancer treatment.
  • Further research into SWI/SNF dependencies could lead to novel anti-cancer drugs.
Keywords:
SWI/SNFcancer therapysynthetic lethality

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

12.8K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K